RT Book, Section A1 El-Haddad, Ghassan A1 Hess, Søren A1 Alavi, Abass A2 Grippi, Michael A. A2 Antin-Ozerkis, Danielle E. A2 Dela Cruz, Charles S. A2 Kotloff, Robert M. A2 Kotton, Camille Nelson A2 Pack, Allan I. SR Print(0) ID 1194948825 T1 Physiologic and Metabolic Assessment of Pulmonary Disorders Using Conventional Imaging Techniques and Positron Emission Tomography T2 Fishman’s Pulmonary Diseases and Disorders, 6e YR 2023 FD 2023 PB McGraw-Hill Education PP New York, NY SN 9781260473988 LK accessmedicine.mhmedical.com/content.aspx?aid=1194948825 RD 2025/03/24 AB Since the mid-1950s, use of radiopharmaceuticals has made it possible to assess a variety of pulmonary disorders. In 1955, 133Xe was introduced for the study of regional pulmonary ventilation.1 Shortly thereafter, it became possible to evaluate regional pulmonary blood flow using inhaled carbon dioxide containing radioactive 15O2 or intravenous injection of 133Xe dissolved in saline solution.3 In 1964, intravenous injection of 131I-macroaggregated albumin made it feasible to obtain perfusion scans of the lungs.4 Although these techniques rapidly gained wide acceptance as tests of regional abnormalities in ventilation and pulmonary blood flow, the main practical application was as a ventilation–perfusion lung scan (V̇/Q̇ scan) in the diagnostic evaluation of patients with suspected pulmonary embolism. Over the years, the role of nuclear medicine in respiratory medicine expanded to include such indications as preoperative assessment of lung function, mucociliary clearance, alveolar-capillary membrane permeability, inflammatory lung disease, and lung cancer. The last two indications were facilitated by the more widespread availability of positron emission tomography (PET) and integrated PET/CT (computed tomography) that has provided powerful tools to aid in the diagnosis, staging, and management of patients.